Trials / Completed
CompletedNCT01822249
Phase 2 Study of EPI-743 for Treatment of Rett Syndrome
A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Edison Pharmaceuticals Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Rett syndrome is a severe neurodevelopmental disorder that primarily affects female children. Rett syndrome is characterized by significant elevation in blood markers of oxidative stress. EPI-743 is a novel therapeutic with demonstrated efficacy and safety in the treatment of disorders characterized by oxidative stress. The purpose of this study is to examine the safety and efficacy of EPI-743 in a population of children with Rett syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPI-743 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-12-01
- Completion
- 2014-01-01
- First posted
- 2013-04-02
- Last updated
- 2018-07-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01822249. Inclusion in this directory is not an endorsement.